Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.0800 (0.5%) ($11.9400 - $12.5800) on Thu. Apr. 23, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.09% (three month average) | RSI | 77 | Latest Price | $12.0800(0.5%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 2.5% a day on average for past five trading days. | Weekly Trend | FOLD advances 10.8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(55%) XBI(51%) IWO(50%) IWM(46%) IWC(44%) | Factors Impacting FOLD price | FOLD will decline at least -3.545% in a week (0% probabilities). VIXM(-28%) VXX(-15%) UUP(-11%) TLT(-4%) UNG(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.545% (StdDev 7.09%) | Hourly BBV | 0 () | Intraday Trend | 0.5% | | | |
|
5 Day Moving Average | $11.89(1.6%) | 10 Day Moving Average | $11.15(8.34%) | 20 Day Moving Average | $10.37(16.49%) | To recent high | 0% | To recent low | 82.2% | Market Cap | $3.119b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |